| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050512946 |
| P356 | DOI | 10.1111/J.1523-1755.2005.00267.X |
| P698 | PubMed publication ID | 15840016 |
| P5875 | ResearchGate publication ID | 7897451 |
| P2093 | author name string | Carla G Monico | |
| Dawn S Milliner | |||
| Julie B Olson | |||
| Sandro Rossetti | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary hyperoxaluria | Q7243137 |
| pyridoxine | Q423746 | ||
| P304 | page(s) | 1704-1709 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele | |
| P478 | volume | 67 |
| Q37032683 | Actualizing the Benefits of Genomic Discovery in Pediatric Nephrology |
| Q38017938 | An update on primary hyperoxaluria |
| Q35661403 | Assay strategies for identification of therapeutic leads that target protein trafficking |
| Q40821949 | Biochemical analyses are instrumental in identifying the impact of mutations on holo and/or apo-forms and on the region(s) of alanine:glyoxylate aminotransferase variants associated with primary hyperoxaluria type I. |
| Q89864261 | Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening |
| Q24302592 | Consequences of missense mutations for dimerization and turnover of alanine:glyoxylate aminotransferase: study of a spectrum of mutations |
| Q30834734 | Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type |
| Q34547086 | Diet and fluid prescription in stone disease |
| Q26864796 | Drug treatment of inborn errors of metabolism: a systematic review |
| Q40015456 | Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay. |
| Q34175404 | Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. |
| Q90280443 | Endpoints for Clinical Trials in Primary Hyperoxaluria |
| Q82875562 | Evidence of true genotype-phenotype correlation in primary hyperoxaluria type 1 |
| Q42971094 | Excellent renal function and reversal of nephrocalcinosis 8 years after isolated liver transplantation in an infant with primary hyperoxaluria type 1. |
| Q47602222 | Folding Defects Leading to Primary Hyperoxaluria |
| Q35124270 | Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. |
| Q58118152 | Genetic Causes of Kidney Stones and Kidney Failure |
| Q37512167 | Genetic determinants of urolithiasis |
| Q43218013 | Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome |
| Q34066169 | Hereditary causes of kidney stones and chronic kidney disease |
| Q38061207 | Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions |
| Q36613873 | Hyperoxaluria and systemic oxalosis: current therapy and future directions |
| Q53105737 | Hyperoxaluria, hyperglycoluria and renal oxalosis in Gilbert's potoroos (Potorous gilbertii). |
| Q27013855 | Hyperoxaluria: a gut-kidney axis? |
| Q63441488 | Hyperoxalurie primitive |
| Q46913576 | Identification of a novel AGXT gene mutation in primary hyperoxaluria after kidney transplantation failure |
| Q42026779 | Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations |
| Q46453748 | Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria |
| Q44012648 | Is there a genotype-phenotype correlation in primary hyperoxaluria type 1? |
| Q34935451 | Kidney stones in primary hyperoxaluria: new lessons learnt |
| Q37169623 | Kidney stones: an update on current pharmacological management and future directions |
| Q33392071 | Living donor kidney transplantation in patients with hereditary nephropathies |
| Q37422038 | Lowering urinary oxalate excretion to decrease calcium oxalate stone disease |
| Q42103822 | Molecular Insight into the Synergism between the Minor Allele of Human Liver Peroxisomal Alanine:Glyoxylate Aminotransferase and the F152I Mutation |
| Q51029593 | Molecular analysis of the AGXT gene in patients suspected with hyperoxaluria type 1 and three novel mutations from Turkey. |
| Q28257183 | Molecular etiology of primary hyperoxaluria type 1: new directions for treatment |
| Q45866877 | Molecular therapy of primary hyperoxaluria |
| Q30403926 | Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria |
| Q35798380 | Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria |
| Q46617816 | Partial trypsin digestion as an indicator of mis-folding of mutant alanine:glyoxylate aminotransferase and chaperone effects of specific ligands. Study of a spectrum of missense mutants. |
| Q36033738 | Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies. |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q36104822 | Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria |
| Q36432868 | Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure |
| Q80124022 | Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: Single-center experience |
| Q58583358 | Primary Hyperoxaluria Type 1 with Thrombophilia in Pregnancy: A Case Report |
| Q35567868 | Primary and secondary hyperoxaluria: Understanding the enigma |
| Q35073045 | Primary hyperoxaluria |
| Q38445799 | Primary hyperoxaluria type 1 in 18 children: genotyping and outcome |
| Q43990085 | Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort |
| Q36524018 | Primary hyperoxaluria type 1: still challenging! |
| Q37500313 | Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. |
| Q38292247 | Primary hyperoxalurias: diagnosis and treatment |
| Q29147458 | Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria |
| Q38129886 | Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I. |
| Q30355120 | Protein homeostasis disorders of key enzymes of amino acids metabolism: mutation-induced protein kinetic destabilization and new therapeutic strategies. |
| Q83445877 | Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients |
| Q90395008 | Recent advances in the identification and management of inherited hyperoxalurias |
| Q43246859 | Reconstruction of human hepatocyte glyoxylate metabolic pathways in stably transformed Chinese-hamster ovary cells. |
| Q26784171 | Recurrence of crystalline nephropathy after kidney transplantation in APRT deficiency and primary hyperoxaluria |
| Q33911824 | Selected AGXT gene mutations analysis provides a genetic diagnosis in 28% of Tunisian patients with primary hyperoxaluria |
| Q35977167 | Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant |
| Q27680557 | The Role of Protein Denaturation Energetics and Molecular Chaperones in the Aggregation and Mistargeting of Mutants Causing Primary Hyperoxaluria Type I |
| Q30797651 | The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre. |
| Q83370521 | The primary hyperoxalurias |
| Q34247162 | Transplantation Outcomes in Primary Hyperoxaluria |
| Q80307057 | Treatment of the primary hyperoxalurias: a new chapter |
| Q37267462 | Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones |
| Q38105961 | Update on oxalate crystal disease |
| Q57818861 | Updated Genetic Testing of Primary Hyperoxaluria Type 1 in a Chinese Population: Results from a Single Center Study and a Systematic Review |
| Q40013197 | Urine oxalate biological variation in patients with primary hyperoxaluria |
| Q37621553 | Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice |
| Q48182454 | Vitamin B6 intake and the risk of incident kidney stones. |
Search more.